Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MDXG's Cash to Debt is ranked higher than
88% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. MDXG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MDXG' s 10-Year Cash to Debt Range
Min: 0  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.82
MDXG's Equity to Asset is ranked higher than
79% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. MDXG: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
MDXG' s 10-Year Equity to Asset Range
Min: 0.44  Med: 0.82 Max: 0.89
Current: 0.82
0.44
0.89
Interest Coverage No Debt
MDXG's Interest Coverage is ranked higher than
82% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. MDXG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MDXG' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 6
Z-Score: 31.04
M-Score: -2.16
WACC vs ROIC
19.19%
43.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 11.46
MDXG's Operating margin (%) is ranked higher than
75% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. MDXG: 11.46 )
Ranked among companies with meaningful Operating margin (%) only.
MDXG' s 10-Year Operating margin (%) Range
Min: -1334.98  Med: -19.79 Max: 6.01
Current: 11.46
-1334.98
6.01
Net-margin (%) 10.69
MDXG's Net-margin (%) is ranked higher than
80% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. MDXG: 10.69 )
Ranked among companies with meaningful Net-margin (%) only.
MDXG' s 10-Year Net-margin (%) Range
Min: -1447.4  Med: -28.32 Max: 5.26
Current: 10.69
-1447.4
5.26
ROE (%) 20.07
MDXG's ROE (%) is ranked higher than
90% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. MDXG: 20.07 )
Ranked among companies with meaningful ROE (%) only.
MDXG' s 10-Year ROE (%) Range
Min: -276.61  Med: -113.28 Max: 7.64
Current: 20.07
-276.61
7.64
ROA (%) 16.63
MDXG's ROA (%) is ranked higher than
95% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: -0.62 vs. MDXG: 16.63 )
Ranked among companies with meaningful ROA (%) only.
MDXG' s 10-Year ROA (%) Range
Min: -557.14  Med: -81.88 Max: 6.41
Current: 16.63
-557.14
6.41
ROC (Joel Greenblatt) (%) 74.88
MDXG's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. MDXG: 74.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDXG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2458.54  Med: -847.17 Max: 39.25
Current: 74.88
-2458.54
39.25
Revenue Growth (3Y)(%) 111.50
MDXG's Revenue Growth (3Y)(%) is ranked higher than
100% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. MDXG: 111.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDXG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 293.6
Current: 111.5
0
293.6
» MDXG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MDXG Guru Trades in Q3 2014

Joel Greenblatt 17,878 sh (New)
Jim Simons 251,000 sh (+39.52%)
Steven Cohen 825,000 sh (-9.02%)
» More
Q4 2014

MDXG Guru Trades in Q4 2014

Paul Tudor Jones 19,098 sh (New)
Joel Greenblatt 36,045 sh (+101.62%)
Steven Cohen Sold Out
Jim Simons 198,172 sh (-21.05%)
» More
Q1 2015

MDXG Guru Trades in Q1 2015

Steven Cohen 942,500 sh (New)
Paul Tudor Jones 38,800 sh (+103.16%)
Joel Greenblatt 61,414 sh (+70.38%)
Jim Simons 174,400 sh (-12.00%)
» More
Q2 2015

MDXG Guru Trades in Q2 2015

Jim Simons 581,500 sh (+233.43%)
Joel Greenblatt 56,809 sh (-7.50%)
Steven Cohen 834,300 sh (-11.48%)
Paul Tudor Jones 34,200 sh (-11.86%)
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 61.52
MDXG's P/E(ttm) is ranked lower than
82% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 28.00 vs. MDXG: 61.52 )
Ranked among companies with meaningful P/E(ttm) only.
MDXG' s 10-Year P/E(ttm) Range
Min: 59.58  Med: 166.43 Max: 5530
Current: 61.52
59.58
5530
Forward P/E 35.97
MDXG's Forward P/E is ranked lower than
74% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.15 vs. MDXG: 35.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 61.10
MDXG's PE(NRI) is ranked lower than
82% of the 153 Companies
in the Global Medical Devices industry.

( Industry Median: 28.00 vs. MDXG: 61.10 )
Ranked among companies with meaningful PE(NRI) only.
MDXG' s 10-Year PE(NRI) Range
Min: 61.07  Med: 177.28 Max: 1843.33
Current: 61.1
61.07
1843.33
P/B 10.94
MDXG's P/B is ranked lower than
92% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. MDXG: 10.94 )
Ranked among companies with meaningful P/B only.
MDXG' s 10-Year P/B Range
Min: 5.5  Med: 11.11 Max: 21.82
Current: 10.94
5.5
21.82
P/S 6.93
MDXG's P/S is ranked lower than
76% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. MDXG: 6.93 )
Ranked among companies with meaningful P/S only.
MDXG' s 10-Year P/S Range
Min: 6.51  Med: 11.68 Max: 148
Current: 6.93
6.51
148
PFCF 58.81
MDXG's PFCF is ranked lower than
75% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 32.61 vs. MDXG: 58.81 )
Ranked among companies with meaningful PFCF only.
MDXG' s 10-Year PFCF Range
Min: 56.94  Med: 77.13 Max: 221.2
Current: 58.81
56.94
221.2
POCF 42.77
MDXG's POCF is ranked lower than
77% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 21.13 vs. MDXG: 42.77 )
Ranked among companies with meaningful POCF only.
MDXG' s 10-Year POCF Range
Min: 41.42  Med: 69.98 Max: 372
Current: 42.77
41.42
372
EV-to-EBIT 53.53
MDXG's EV-to-EBIT is ranked lower than
81% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: 21.01 vs. MDXG: 53.53 )
Ranked among companies with meaningful EV-to-EBIT only.
MDXG' s 10-Year EV-to-EBIT Range
Min: -299.1  Med: -9.20 Max: 1158.8
Current: 53.53
-299.1
1158.8
Current Ratio 4.72
MDXG's Current Ratio is ranked higher than
76% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. MDXG: 4.72 )
Ranked among companies with meaningful Current Ratio only.
MDXG' s 10-Year Current Ratio Range
Min: 0.05  Med: 1.55 Max: 7.08
Current: 4.72
0.05
7.08
Quick Ratio 4.52
MDXG's Quick Ratio is ranked higher than
78% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. MDXG: 4.52 )
Ranked among companies with meaningful Quick Ratio only.
MDXG' s 10-Year Quick Ratio Range
Min: 0.05  Med: 1.54 Max: 6.7
Current: 4.52
0.05
6.7
Days Inventory 94.34
MDXG's Days Inventory is ranked higher than
68% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 130.22 vs. MDXG: 94.34 )
Ranked among companies with meaningful Days Inventory only.
MDXG' s 10-Year Days Inventory Range
Min: 11.88  Med: 129.89 Max: 135.08
Current: 94.34
11.88
135.08
Days Sales Outstanding 90.25
MDXG's Days Sales Outstanding is ranked lower than
65% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.40 vs. MDXG: 90.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDXG' s 10-Year Days Sales Outstanding Range
Min: 74.94  Med: 88.99 Max: 103.26
Current: 90.25
74.94
103.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 41.22
MDXG's Price/Net Cash is ranked lower than
84% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 12.83 vs. MDXG: 41.22 )
Ranked among companies with meaningful Price/Net Cash only.
MDXG' s 10-Year Price/Net Cash Range
Min: 20.43  Med: 41.83 Max: 140
Current: 41.22
20.43
140
Price/Net Current Asset Value 14.36
MDXG's Price/Net Current Asset Value is ranked lower than
73% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 6.85 vs. MDXG: 14.36 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDXG' s 10-Year Price/Net Current Asset Value Range
Min: 11.35  Med: 30.00 Max: 147.5
Current: 14.36
11.35
147.5
Price/Tangible Book 13.17
MDXG's Price/Tangible Book is ranked lower than
85% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.09 vs. MDXG: 13.17 )
Ranked among companies with meaningful Price/Tangible Book only.
MDXG' s 10-Year Price/Tangible Book Range
Min: 10.57  Med: 29.94 Max: 237.5
Current: 13.17
10.57
237.5
Price/Projected FCF 17.89
MDXG's Price/Projected FCF is ranked lower than
92% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. MDXG: 17.89 )
Ranked among companies with meaningful Price/Projected FCF only.
MDXG' s 10-Year Price/Projected FCF Range
Min: 21.87  Med: 28.83 Max: 354.5
Current: 17.89
21.87
354.5
Price/Median PS Value 0.58
MDXG's Price/Median PS Value is ranked higher than
86% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. MDXG: 0.58 )
Ranked among companies with meaningful Price/Median PS Value only.
MDXG' s 10-Year Price/Median PS Value Range
Min: 0.63  Med: 1.00 Max: 11.25
Current: 0.58
0.63
11.25
Price/Graham Number 5.93
MDXG's Price/Graham Number is ranked lower than
82% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 2.22 vs. MDXG: 5.93 )
Ranked among companies with meaningful Price/Graham Number only.
MDXG' s 10-Year Price/Graham Number Range
Min: 7.24  Med: 10.27 Max: 20.37
Current: 5.93
7.24
20.37
Earnings Yield (Greenblatt) (%) 1.81
MDXG's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 0.40 vs. MDXG: 1.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDXG' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 0.80 Max: 1.9
Current: 1.81
0.1
1.9

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 187 240 293
EPS($) 0.22 0.26 0.38
EPS without NRI($) 0.22 0.26 0.38

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:MXE.Germany,
MiMedx Group Inc was incorporated in Florida on February 28, 2008. The Company develops clinical solutions for the use of its biomaterials to regenerate soft tissue in wound healing, orthopedics and other specialty fields of medicine. It is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFixM, and its tissue technologies, AmnioFix and EpiFix. It is a supplier of allografts processed from amniotic tissue, having supplied approximately over 200,000 allografts to date for application in the Surgical, Orthopedic, Spinal, Wound Care, Ophthalmic, and Dental segments of healthcare. Its technology and products are Purion, AmnioFix, EpiFix and other Tissue -Based Allografts and Medical Devices- CollaFix and HydroFix. The Company operates a licensed tissue bank. Its solutions are being used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds.
» More Articles for MDXG

Headlines

Articles On GuruFocus.com
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial... Aug 27 2015
MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial... Aug 27 2015
MiMedx Announces Publication Of Latest Scientific Study Demonstrating The Ability Of Its Allografts... Aug 26 2015
MiMedx Group, Inc. Q2 Earnings, 2015 Aug 25 2015
MiMedx Patent Infringement Lawsuits Receive Favorable Rulings From Patent Trial And Review Board Aug 21 2015
MiMedx Patent Infringement Lawsuits Receive Favorable Rulings From Patent Trial And Review Board Aug 21 2015
MIMEDX GROUP, INC. Financials Aug 20 2015
10-Q for MiMedx Group, Inc. Aug 09 2015
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 07 2015
MiMedx Updates Second Quarter Information Aug 06 2015
MiMedx Updates Second Quarter Information Aug 06 2015
MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference Aug 03 2015
Edited Transcript of MDXG earnings conference call or presentation 30-Jul-15 2:30pm GMT Jul 31 2015
MIMEDX GROUP INC Earnings Call scheduled for 10:30 am ET today Jul 30 2015
MiMedx beats 2Q profit forecasts Jul 30 2015
MiMedx beats 2Q profit forecasts Jul 30 2015
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 30 2015
MiMedx Announces Record Results for Second Quarter of 2015 Jul 30 2015
MiMedx Announces Record Results for Second Quarter of 2015 Jul 30 2015
Q2 2015 MiMedx Group Inc Earnings Release - Before Market Open Jul 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK